Sana Biotechnology Inc. (SANA)
NASDAQ: SANAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 10:45 AM ET
SANA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $811.27M
- EPS (TTM)
- -$0.76
- Dividend yield
- None
- 52-week range
- 2.61 – 6.55
- Day range
- 2.66 – 2.74
- Volume / Avg
- 599.22K / 3.10M
- Beta
- —
- Shares outstanding
- 299.36M
- Next earnings
- Nov 5, 2026
52-week range
SANA stock today
Sana Biotechnology (SANA) is trading at $2.71 on Oct 8, down 0.37% (-$0.01), versus the S&P 500's 0.19% decline. Shares are 58.6% below their 52-week high of $6.55, set on Oct 15, 2025 and 3.8% above the 52-week low of $2.61, near the bottom of the past year's range. SANA is down 33.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 34.0%.
Sana Biotechnology has posted a net loss over the last twelve months (EPS of -$0.76), so its P/E ratio is not meaningful. Sana Biotechnology's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Sana Biotechnology
Company profileSana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Steven D. Harr M.D.
- Headquarters
- Seattle, WA
- Employees
- 142
- IPO year
- 2021
- Website
- sana.com
Analyst forecast
ForecastConsensus (9 analysts)
none
Avg. price target
$8.43+211.07%
- Strong buy 2
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.18
Sana Biotechnology peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SLBTSL Science Holding Limited | 1.51 | 0.00% | $846.75M | vs SANA |
| GLUEMonte Rosa Therapeutics Inc. | 9.93 | -2.39% | $846.89M | vs SANA |
| ODTXOdyssey Therapeutics Inc. | 18.07 | -0.06% | $868.42M | vs SANA |
| DNAGinkgo Bioworks Holdings Inc. Class A | 11.17 | -2.66% | $751.88M | vs SANA |
| CADLCandel Therapeutics Inc. | 9.58 | -2.44% | $733.05M | vs SANA |
| CGEMCullinan Therapeutics Inc. | 14.99 | -4.13% | $920.95M | vs SANA |
| ATTOAttovia Therapeutics Inc. | 15.84 | -3.56% | $722.89M | vs SANA |
| SLDBSolid Biosciences Inc. | 6.69 | -2.41% | $716.80M | vs SANA |
Indexes, lists and sector
Sana Biotechnology stock FAQ
What is Sana Biotechnology's stock price today?
SANA last traded at $2.71 as of Oct 8, 10:45 AM EDT, down 0.37% on the day. Prices are delayed at least 15 minutes.
When is Sana Biotechnology's next earnings date?
Sana Biotechnology is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.18.
Who is Sana Biotechnology's CEO?
Dr. Steven D. Harr M.D. is the chief executive officer of Sana Biotechnology Inc., which has about 142 employees.
What is the SANA 52-week high?
The 52-week high for SANA is $6.55 and the 52-week low is $2.61. The stock is currently 58.6% below its high.